BMY Jun 2024 48.000 put
| Previous Close | 5.75 |
| Open | 5.42 |
| Bid | 5.25 |
| Ask | 5.40 |
| Strike | 48.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 5.42 - 5.53 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.77k |
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
- ACCESSWIRE
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries PRINCETON, NJ / ACCESSWIRE / May 22, 2024 /Bristol Myers Squibb (NYSE:BMY) ...
PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
